Importantly, by combining both elements of CDK4/6 response, it is possible to parse the current proliferative/non-proliferative subtypes into additional prognostic groups that could have significance in assessing risk of recurrence in ER+/HER2- breast cancer. The gene discussed is CDK4; the disease is breast cancer.